Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at **** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Sales from the United States contributed more than 38 billion U.S. dollars towards Pfizer's total revenue of around 63.6 billion U.S. dollars in 2023. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to company revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

In fiscal year 2024, Pfizer's revenue by geographical region are as follows: Developed Rest Of World: $16.06 B, Emerging Markets: $8.88 B, UNITED STATES: $38.69 B.

Revenues generated from outside the United States accounted for almost two thirds of Pfizer's total revenue in 2024. During that year, the company generated revenues of roughly ** billion U.S. dollars in countries outside the United States. China emerges as an important market Pfizer sells its pharmaceutical products in more than *** countries worldwide, with the United States, China, and Japan being among the major national markets. In 2024, the United States alone contributed a share of more than ** percent. In terms of geographic area, emerging markets – which include China – generated revenues of approximately *** billion U.S. dollars in 2024. Analyzing Pfizer’s global operations In 2024, Pfizer had approximately 81,000 employees worldwide. The American company had ** manufacturing sites in countries ranging from Belgium to Singapore, each producing products that serviced the company’s commercial division. Pfizer also had several facilities that focused on research and development projects, many of which were located in North America.

Pfizer reported $13.72B in Sales Revenues for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Pfizer's annual revenue was $63.63 B in fiscal year 2024. The annual revenue increased $5.13 B from $58.50 B (in 2023) to $63.63 B (in 2024), representing a 8.77% year-over-year growth.

In 2024, Pfizer generated total revenues of some **** billion U.S. dollars. For Q1, 2025, the company reported revenues of some **** billion U.S. dollars. That was significantly lower than in the same quarter in 2024. By failing to prepare, you are preparing to fail The majority of Pfizer’s revenue comes from the manufacture and sale of its products. Pharmaceutical companies are always planning for the future, looking for ways to offset the impact felt when those products start to lose market exclusivity. The development of products is essential for the continued growth of the company, and investing in research and development (R&D) is one way of identifying new, innovative medicines. Pfizer’s R&D expenditure stood at around **** billion U.S. dollars in 2024. Why Pfizer’s revenues decreased until 2020? Pfizer averaged quarterly revenues of around **** billion U.S. dollars in the four years from the start of 2016 to the end of 2019 – this is considerably lower than the **** billion U.S. dollars the company averaged per quarter in 2010. One reason for the decline was competition from generic drugs that entered the market when key patents expired. Pfizer lost the market exclusivity for its Lipitor product at the end of 2011, and revenues were greatly affected as a consequence. Additionally, following a review of its product portfolio, Pfizer’s revenues were also impacted by the decision to spin off some of its business segments, such as its animal health division in 2013 and its Upjohn business in 2020.

In fiscal year 2024, Pfizer's revenue by segment (products & services) are as follows: Biopharma Segment: $62.40 B.

This statistic depicts revenues of pharmaceutical company Pfizer from 2022 to 2024, by segment. The Primary Care segment, which includes the COVID-19 vaccine Comirnaty, is the company's ********* segment. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. Due to the Upjohn spin-off during 2020 and the Consumer Healthcare business merger with GSK's consumer health segment to form a new joint venture in 2019, only the Biopharma segment remained.

Pfizer reported $3.67B in Operating Profit for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Operating Profit including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Pfizer reported $2.97B in Net Income for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Net Income including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Pfizer pre-tax profit margin for the quarter ending March 31, 2025 was 11.83%. Pfizer average pre-tax profit margin for 2024 was 2.12%, a 89.31% increase from 2023. Pfizer average pre-tax profit margin for 2023 was 19.84%, a 38.67% decline from 2022. Pfizer average pre-tax profit margin for 2022 was 32.35%, a 20.89% decline from 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

The net income of Pfizer stood at some ***** billion U.S. dollars in 2024. In the preceding year, the net income was at over *** billion U.S. dollars. What factors affect net income? Companies discover how much they have earned or lost during an accounting period by analyzing their net income. For example, rising costs are among several reasons for the significant fall in Pfizer’s net income in 2020: the company increased its research and development expenditure, and suffered additional costs associated with the restructuring of the organization. It is worth adding that the high net income in 2017 was favorably impacted by a tax benefit of around **** billion U.S. dollars. The pros and cons of mergers and acquisitions Mergers and acquisitions are a common business strategy used by companies looking to grow. ***** of the largest deals in pharmaceutical industry history involve Pfizer, including its acquisition of Warner-Lambert for a record fee of around ** billion U.S. dollars in 2000. Advantages of the tactic include a larger workforce, increased spending budgets, and breaking into new markets. However, a failure to anticipate potential problems can be damaging to a company. For instance, the integration may disrupt current business operations, and inconsistencies may start to appear in standards and procedures.

Pfizer reported $2.59B in Cost of Sales for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last June in 2025.

Pfizer reported $11.12B in Gross Profit on Sales for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Gross Profit On Sales including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Pfizer net income/loss for the twelve months ending March 31, 2025 was $21.850B, a 16.89% increase year-over-year. Pfizer annual net income/loss for 2024 was $8.062B, a 273.59% increase from 2023. Pfizer annual net income/loss for 2023 was $2.158B, a 93.13% decline from 2022. Pfizer annual net income/loss for 2022 was $31.407B, a 42.6% increase from 2021.

Pfizer reported $5.93B in EBIT for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Ebit including historical, tables and charts were last updated by Trading Economics this last July in 2025.

The graph depicts Pfizer's top 10 products based on revenue in 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's top product was Eliquis. COVID-19 vaccine Comirnaty, on the other hand, showed another dramatic decline in sales from **** billion U.S. dollars in 2023 to *** billion dollars. Pfizer's top productsPfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in **** by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2024, Pfizer generated a total revenue of **** billion U.S. dollars worldwide, with oncology products accumulating some **** billion U.S. dollars.Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around *** and * billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of **** billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under * billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.

Introduction

Pfizer Statistics: As one of the foremost companies in the pharmaceutical sector, Pfizer has successfully embedded itself in the healthcare sector. By 2024, the company’s advancements are attributed to the innovation of vaccines, prescription drugs, and biotechnological products.

Pfizer statistics in the year 2024, with emphasis on revenue, market share, R&D expenditure, and major achievements, are presented below.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data was reported at 1,753,000.000 USD th in Jun 2018. This records an increase from the previous number of 812,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,980,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 3,433,000.000 USD th in Dec 2017 and a record low of 707,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.